Morgan Stanley raised the firm’s price target on Zenas BioPharma (ZBIO) to $22 from $21 and keeps an Equal Weight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma
- Zenas BioPharma doses first patient in Phase 1 clinical trial of ZB021
- Zenas BioPharma Highlights Strong Q1 Progress and Financing
- Zenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year
- Zenas BioPharma, Inc. (ZBIO) Q1 Earnings Cheat Sheet